Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overcoming Antigen Escape with CAR T-cell Therapy.

Literature DB >> 26637657

Overcoming Antigen Escape with CAR T-cell Therapy.

Abstract

Sotillo and colleagues describe the molecular events associated with apparent loss of target antigen expression following CAR T-cell therapy. We propose that broader immune activation is required to prevent outgrowth of tumor antigen escape variants following targeted therapies. ©2015 American Association for Cancer Research.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2015 PMID： 26637657 PMCID： PMC5536095 DOI： 10.1158/2159-8290.CD-15-1275

Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397

9 in total

Review 1. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

Authors: Hollie J Pegram; Eric L Smith; Sarwish Rafiq; Renier J Brentjens
Journal: Immunotherapy Date: 2015 Impact factor: 4.196

2. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors: Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal: Cancer Discov Date: 2015-10-29 Impact factor: 39.397

3. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors: Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal: Lancet Date: 2014-10-13 Impact factor: 79.321

4. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

Authors: Kevin J Curran; Beatrijs A Seinstra; Yan Nikhamin; Raymond Yeh; Yelena Usachenko; Dayenne G van Leeuwen; Terence Purdon; Hollie J Pegram; Renier J Brentjens
Journal: Mol Ther Date: 2015-01-13 Impact factor: 11.454

5. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors: Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal: Blood Date: 2012-02-21 Impact factor: 22.113

6. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal: Science Date: 2015-03-12 Impact factor: 47.728

7. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.

Authors: Matthias T Stephan; Vladimir Ponomarev; Renier J Brentjens; Alex H Chang; Konstantin V Dobrenkov; Glenn Heller; Michel Sadelain
Journal: Nat Med Date: 2007-11-18 Impact factor: 53.440

8. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors: Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal: Nature Date: 2011-11-23 Impact factor: 49.962

9. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

Authors: Meenakshi Hegde; Amanda Corder; Kevin K H Chow; Malini Mukherjee; Aidin Ashoori; Yvonne Kew; Yi Jonathan Zhang; David S Baskin; Fatima A Merchant; Vita S Brawley; Tiara T Byrd; Simone Krebs; Meng Fen Wu; Hao Liu; Helen E Heslop; Stephen Gottschalk; Stephen Gottachalk; Eric Yvon; Nabil Ahmed
Journal: Mol Ther Date: 2013-08-13 Impact factor: 11.454

9 in total

33 in total

1. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.

Authors: Junyun Lai; Sherly Mardiana; Imran G House; Kevin Sek; Melissa A Henderson; Lauren Giuffrida; Amanda X Y Chen; Kirsten L Todd; Emma V Petley; Jack D Chan; Emma M Carrington; Andrew M Lew; Benjamin J Solomon; Joseph A Trapani; Katherine Kedzierska; Maximilien Evrard; Stephin J Vervoort; Jason Waithman; Phillip K Darcy; Paul A Beavis
Journal: Nat Immunol Date: 2020-05-18 Impact factor: 25.606

10. Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.

Authors: Laura K Fogli; Rosemarie Aurigemma; Connie L Sommers; Anju Singh; Kasia Bourcier; Marc S Ernstoff
Journal: J Immunother Cancer Date: 2021-07 Impact factor: 13.751

Overcoming Antigen Escape with CAR T-cell Therapy.

Review 1. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

2. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

3. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

4. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

5. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

6. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

7. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.

8. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

9. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

1. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.

2. Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

Review 3. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.

Review 4. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.

5. N-dihydrogalactochitosan as a potent immune activator for dendritic cells.

6. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.

7. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.

Review 8. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.

Review 9. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.

10. Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.